Email updates

Keep up to date with the latest news and content from BMC Medical Physics and BioMed Central.

Open Access Highly Accessed Research article

188Re radiopharmaceuticals for radiosynovectomy: evaluation and comparison of tin colloid, hydroxyapatite and tin-ferric hydroxide macroaggregates

Eduardo Savio1*, María Cristina Ures1, Patricia Zeledón2, Victoria Trindade1, Andrea Paolino1, Virginia Mockford1, Antonio Malanga3, Marcelo Fernández1 and Javier Gaudiano4

Author Affiliations

1 Cátedra de Radioquímica. Facultad de Química. Universidad de la República. Montevideo, Uruguay

2 Servicio de Medicina Nuclear. Hospital San Juan de Dios. San José de Costa Rica, Costa Rica

3 Cátedra de Farmacotecnia. Facultad de Química. Universidad de la República. Montevideo, Uruguay

4 Centro de Medicina Nuclear. Hospital de Clínicas. Facultad de Medicina. Universidad de la República. Montevideo, Uruguay

For all author emails, please log on.

BMC Nuclear Medicine 2004, 4:1  doi:10.1186/1471-2385-4-1

Published: 30 January 2004

Abstract

Background

Radiosynovectomy is a therapy used to relieve pain and inflammation from rheumatoid arthritis and related diseases. In this study three 188Re particulate compounds were characterized according to their physico-chemical properties and their biological behavior in rabbits. The results were compared in order to establish which was the radiopharmaceutical that better fits the requirements of this kind of radiotherapy.

Methods

Three radiopharmaceutical formulations, tin colloid, hydroxyapatite particles (HA) and ferric hydroxide macroaggregates coated with tin colloid (FHMA), were physically characterized (number, volume and surface of the particles). For this purpose laser diffraction methodology was used. To evaluate cavity leakage of activity the following studies in New Zealand rabbits were performed: scintigraphic images for 48 hr after intraarticular injection of each radiopharmaceutical, biodistribution at 48 hr and urine samples collection during the first 24 hr post-radiopharmaceutical administration.

Results

Labeling procedures for 188Re-HA and 188Re-Sn-FHMA were labour intensive while 188Re-Sn was easily prepared. Furthermore, 188Re-Sn colloid offered the greatest surface area in the 2–10 microm range and was obtained with a radiochemical purity over 95%, while percentage of bound activity for 188Re-HA and 188Re-Sn-FHMA were 55% and 92% respectively. Stability was verified for the three radiopharmaceuticals for 24 hr. Scintigraphic studies and biodistribution in rabbits after intraarticular administration of the radiopharmaceuticals showed relevant activity only in the knee, this being over 90% of the residual activity in the whole body at 48 hr in every case. Renal elimination of 188Re-Sn colloid and 188Re-Sn-FHMA was detected by activity measurements in urine samples, during the first 12 hr post-radiopharmaceutical injection.

The percentage of activity retained in the knee was 69.1% for 188Re-Sn colloid, 55.1% for 188Re-Sn-FHMA and 33.6% for 188Re-HA.

Conclusion

The 188Re-Sn colloid was easy to prepare, minimum facilities were required, was stable for 24 hr and showed minimal leakage from the joint after intraarticular injection into the rabbit's knee. Furthermore, 188Re-Sn colloid has greater retention in the knee when it is compared with the other radiopharmaceuticals, so it could provide the best therapeutic effect/absorbed dose ratio for the patient.